A number of cases of allogeneic hematopoietic stem cell transplant (allo-HCT) patients presenting with donor-derived neoplasms (DDN) has been reported. 1, 2 Even if the morphological findings were identical, host-derived therapy-related myeloid neoplasms (t-MN) and DDN are distinct diseases, with potentially different treatments. 3 However, the current World Health Organization classification does not distinguish them, which is misleading, as the transplanted cells of DDN were never exposed to mutagenic agents used for the patient's original disease.
On the basis of the distinct pathophysiology driving DDN versus therapy-related myeloid neoplasms, distinguishing them is clinically relevant. If a post allo-HCT neoplasm is determined to be host-derived, reduction of immunosuppression and donor lymphocyte infusion would be considered. 4 This approach would not be favored if the new malignancy was donor-derived, in which case a search for another allogeneic stem cell donor could be warranted.
No single diagnostic test cements the diagnosis of DDN. Molecular chimerism studies or conventional karyotyping (in gender-mismatched transplants) can establish genome-of-origin, provided that the sample is representative of the neoplastic population. However, it can be difficult to obtain a bone marrow aspirate suitable for chimerism studies in patients with marrow fibrosis.
Here we report six new cases of DDN. Two of these highlight a weakness in the current diagnostic menu, as adequate aspirates were unavailable for chimerism studies. To circumvent this challenge, we conducted STR analysis directly from the core biopsy (please see Supplementary Data for methods of tissue dissection, DNA extraction and STR analysis). To our knowledge, these represent the first two cases where chimerism analysis conducted on histologic tissue enabled the diagnosis of DDN.
Case 1 A 57-year-old man with Sezary syndrome refractory to CHOP and vorinostat underwent matched sibling allo-HCT. A recurrence 2 years later was treated with radiation therapy, brentuximab and donor lymphocyte infusion. The skin lesions resolved, but pancytopenia developed, and he was diagnosed with AML 5 years post transplant.
The marrow was inaspirable at the time of AML diagnosis; biopsy showed 30% blasts with marked fibrosis (Figure 1 ). Chimerism studies, essentially performed on peripheral blood, showed 98% donor DNA, 2% recipient DNA. Peripheral blood showed only 6% leukemic blasts. Cytogenetics showed normal karyotype.
Chimerism analysis performed directly on core biopsy containing malignant blasts showed 90% donor DNA, confirming DDN. The patient's brother, 54 at the time of donation, has remained healthy with normal complete blood count (CBC). The patient subsequently underwent an unrelated donor HCT.
Case 2 A 69-year-old man with history of CLL with transformation to DLBCL was treated with R-CHOP followed by haploidentical transplant from his son. He also received post-transplant cyclophosphamide. Eighteen months post transplant, he developed pancytopenia. His marrow showed AML with 60% blasts, dysplastic megakaryocytes and extensive fibrosis. The marrow was inaspirable and peripheral blood showed no leukemic blasts. Chimerism studies from peripheral blood showed 99% donor DNA, 1% recipient DNA.
Cytogenetics showed abnormal male karyotype with loss or deletion of chromosomes 4 and 5q, 7q36, 11q, 12p, 16, 17q and 19 and gain of 1p in four of 29 cells. FISH analysis showed deletion of 5q in 27 of 200 interphase cells.
Molecular analysis performed directly on core biopsy tissue containing~60% blasts showed 480% donor DNA ( Figure 1 ).
Case 3
A 58-year-old man with primary refractory follicular lymphoma received a matched sibling donor transplant, and developed anemia (Hemoglobin 13.4 g/dL) and thrombocytopenia (59 000/ μL) 6 years later. His marrow showed myelodysplastic syndrome (MDS) with ringed sideroblasts. Cytogenetics later revealed monosomy 7 in six cells and deletion 20 in nine cells (nonoverlapping). Chimerism studies from an adequate aspirate sample showed 99% donor DNA and 1% recipient DNA, consistent with DDN.
Case 4
An 81-year-old woman with a history of diffuse large B-cell lymphoma (DLBCL) underwent CHOP and achieved CR, but 3 years later, developed chronic myelomonocytic leukemia (CMML) with isochromosome 17q. She received topotecan and Ara-C followed by allo-HCT from a male-matched unrelated donor. Chimerism assessment was consistent with complete donor origin (46,XY).
Eight years post transplant, she developed 'therapy-related' AML. The marrow biopsy showed no significant fibrosis, and aspirate demonstrated 77% blasts. Although chimerism studies were not available after development of AML, karyotype of her marrow continued to show only XY chromosomes, consistent with DDN. The patient died 2 months after the AML diagnosis.
Case 5
An 82-year-old woman with history of B-cell prolymphocytic leukemia (B-PLL) was treated with fludarabine, cyclophosphamide, rituximab and subsequently, alemtuzumab, and achieved a partial response. She was also treated with R-HyperCVAD for three cycles and underwent splenectomy followed by allo-HCT from a male- matched unrelated donor. One year later, she developed 'therapyrelated' AML and died within a week of diagnosis.
At the time of B-PLL diagnosis, prior to transplant, her bone marrow revealed a complex karyotype. After transplant, and at the time of AML, cytogenetics showed a normal male karyotype, 46,XY. At that time, cytogenetics of the marrow showed 86% donor DNA, 14% recipient. There was no significant marrow fibrosis. Peripheral blood chimerism performed at the time of AML diagnosis showed 100% donor.
Case 6
A 55-year-old woman with follicular lymphoma received CVPRituximab, EPOCH-R and localized radiation followed by reduced intensity SCT from her HLA-matched brother. Prior to transplant, her marrow was morphologically normal but cytogenetics showed deletions of 7q and 20q in one clone. A year post transplant, she had a fall in chimerism, anemia and thrombocytopenia. Host-derived MDS diagnosis was made based on the finding of deletions 5q and 7q in female cells, detected by both FISH testing and karyotyping of the marrow. Immunosuppression was gradually discontinued, whereupon bone marrow chimerism returned to 99% donor and karyotype normalized.
Five years post transplant, she developed pancytopenia and underwent another bone marrow biopsy, which showed RAEB-2 with Auer rods. Cytogenetics showed a normal male karyotype, consistent with DDN. FISH for deletions 5q and 7q was negative. The patient received a second reduced intensity allograft from a 22-year-old unrelated male for presumed donor-derived MDS.
DISCUSSION
We describe six patients who, after receiving allo-HCT for lymphoid malignancies, developed myeloid neoplasms, raising the possibility of DDN. In the literature, DDN is rare, with most patients having presented with myeloid malignancies as the primary disease (Table 1) . With respect to the relationship between donor source and DDN, retrospective studies have shown conflicting results with one recent survey showing a higher incidence of DDN after cord blood transplants whereas a smaller study showed no difference between marrow, peripheral blood and umbilical cord stem cell cells. Interestingly, DDN after cord blood transplants have been associated with a shorter latency period, higher incidence of MDS (despite the relative rarity of MDS in children) and a higher incidence of monosomy 7 compared with DDN after bone marrow or PBSC. 1, 5 As the treatment approach is critically different between DDN and host-derived neoplasms, it is important to distinguish the two. We encountered a unique diagnostic challenge when DDN was suspected but aspirate material was unobtainable for chimerism studies. To assess for DDN, we therefore employed direct STR analysis on core and clot biopsy specimens, which demonstrated substantial tumor burden by microscopy.
Recent studies have suggested that in some cases, DDN can be traced back to subclinical, pre-malignant clones, known as Clonal Hematopoiesis of Indeterminate Potential (CHIP), already present in the donor's stem cell population. 6, 7 These cells subsequently acquire further driver mutations within the recipient, leading to DDN. Somatic mutations consistent with clonal hematopoiesis have been seen in 10% of patients over age 65. 8 Similarly, genome-wide association studies show copy number changes in 20q, 5q, 11q and 17q in~2% of healthy individuals over the age of 70. 9, 10 These cells may acquire further driver mutation within the recipient, leading to DDN. These findings are consistent with a multi-hit model for DDN and present the intriguing possibility of profiling potential stem cell donors for CHIP before transplant, and if CHIP is detected, selecting a different donor if available for that patient.
In the present series, we report the fourth case of DDN after haploidentical transplant and post-transplant cyclophosphamide through the example of case 2. 7, 11, 12 As suggested by Gondek et al., 7 it is possible that a high dose of the alkylating agent cyclophosphamide only a few days after transplant may cause additional mutations that facilitate the development of DDN. As post-transplant cyclophosphamide is increasingly used for GVHD prophylaxis in matched sibling donor and matched unrelated donor transplants as well as after haploidentical transplants, further studies are clearly warranted to determine whether the apparent reduction in severe and chronic GVHD is eventually offset by an increased risk of DDN.
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